CEO Albert Bourla refuted a recent story that said Pfizer ( NYSE:PFE ) was in talks with Chinese officials to have medication manufacturers create a generic version of the COVID-19 antiviral Paxlovid.
According to Reuters, Bourla stated at the J.P. Morgan Healthcare Conference, “We have a deal already for the local manufacture of Paxlovid in China.” So, a local partner will make Paxlovid for us, and that partner will then sell it to Chinese customers.
The news service said on January 6 that, according to sources, the Chinese government was trying to make a deal for generic Paxlovid before the Lunar New Year.
Pfizer Stock Analysis by Zacks
Pfizer finished at $47.62 in the most recent trading session, moving -1.59% from the day before. This action was behind the 0.7% daily rise of the S&P 500. The tech-heavy Nasdaq rose 7.5% at the same time as the Dow gained 0.56%.
As of today, shares of the pharmaceutical company were down 7.23% over the previous month, underperforming both the medical sector’s and the S&P 500’s declines of 1.89% and 0.94%, respectively.
Pfizer Stock Up As China Negotiates License For The COVID Medication Paxlovid
As Pfizer nears the deadline for its next earnings report, Wall Street will be watching for encouraging signs. The earliest that can happen is January 31, 2023. Analysts anticipate that Pfizer will announce earnings of $1.09 per share in that report. This would represent a 0.93% increase over last year. The most recent average estimate is that quarterly sales will be $24.14 billion, which is 1.28 percent more than the same time last year.
Click here to read the full article on PressReach.com . Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube